Article Sidebar
Views pdf: 37
INITIAL RESULTS OF TREATING ATRIAL ARRHYTHMIAS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Main Article Content
Abstract
The study was conducted to evaluate the initial results of treating atrial arrhythmias in patients with chronic obstructive pulmonary disease (COPD). There were 10 patients with acute COPD exacerbations (AECOPD) (mean age 74,7 ± 10,2) and 60 stable COPD patients (mean age 70,2 ± 7,9) with significant atrial arrhythmias recruited. The mean follow-up period was about 5 months, with various treatment method. The frequency of premature atrial complexes and the number of patients with 500 or more premature atrial complexes significantly decreased in the stable COPD group, while changes in these indices in the AECOPD group were not statistically significant. The number of patients with atrial fibrillation significantly decreased after treatment in the acute COPD exacerbation group, while there was no significant change in the stable COPD group. Symptom burden according to the EHRA score tended to decrease but was not statistically significant in both patient groups. This study initially shows the diversity in methods and treatment responses for atrial arrhythmias in COPD patients.
Article Details
Keywords
chronic obstructive pulmonary disease (COPD), atrial arrhythmias, atrial fibrillation, premature atrial complexes, treatment
References
2. Desai R, Patel U, Singh S, et al. The burden and impact of arrhythmia in chronic obstructive pulmonary disease: Insights from the National Inpatient Sample. Int J Cardiol. 2019;281:49-55. doi:10.1016/j.ijcard.2019.01.074
3. Ongel EA, Karakurt Z, Salturk C, et al. How do COPD comorbidities affect ICU outcomes? Int J Chron Obstruct Pulmon Dis. 2014;9:1187-1196. doi:10.2147/COPD.S70257
4. Roberts CM, Stone RA, Lowe D, Pursey NA, Buckingham RJ. Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD. 2011;8(5): 354-361. doi:10.3109/ 15412555.2011.600362
5. Xiao X, Han H, Wu C, et al. Prevalence of Atrial Fibrillation in Hospital Encounters With End-Stage COPD on Home Oxygen: National Trends in the United States. Chest. 2019;155(5):918-927. doi:10.1016/j.chest.2018.12.021
6. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
7. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS ONE. 2018;13(3): e0193924. doi:10.1371/journal.pone.0193924
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36): 3599-3726. doi:10.1093/ eurheartj/ehab368
9. Kennedy JI. Clinical Aspects of Amiodarone Pulmonary Toxicity. Clin Chest Med. 1990;11(1): 119-129. doi:10.1016/S0272-5231(21)00676-6
10. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLOS ONE. 2014; 9(11): e113048. doi:10.1371/journal. pone.0113048